Pharmacology · Cardiovascular

Endothelin Pharmacology and Receptor Antagonists

Endothelin-1 receptors, drug class comparison, and safety rules

Endothelin-1 is the most potent endogenous vasoconstrictor, produced by vascular endothelial cells — it acts through two receptor subtypes with opposing effects on vascular tone: ETA on smooth muscle drives sustained vasoconstriction, proliferation, and fibrosis; ETB on endothelium drives vasodilation via nitric oxide and prostacyclin and also clears endothelin-1 from circulation, while ETB on smooth muscle adds further constriction.
ETA receptor activation is the primary driver of pulmonary arterial hypertension pathology — sustained vasoconstriction, smooth muscle proliferation, and vascular remodeling progressively increase pulmonary vascular resistance; all three approved endothelin receptor antagonists block ETA, while the selective versus dual receptor profile determines their individual pharmacology.
Bosentan, the first-in-class dual ETA/ETB antagonist, established proof of concept but carries significant hepatotoxicity risk (~10 percent transaminase elevation requiring monthly liver function tests) and induces CYP3A4 and CYP2C9, reducing warfarin levels and rendering hormonal contraceptives unreliable; cyclosporine co-administration is absolutely contraindicated due to markedly elevated bosentan plasma levels.
Ambrisentan is selectively ETA-blocking, has low hepatotoxicity, and has minimal drug interactions — but its preserved ETB activity leads to higher peripheral edema rates; macitentan is a dual antagonist with tissue penetrance designed to sustain receptor blockade, showed a 45 percent reduction in morbidity and mortality in the SERAPHIN trial, and requires hemoglobin monitoring due to anemia risk.
All three agents share the same class-wide absolute contraindication in pregnancy due to teratogenicity in animal studies at sub-therapeutic doses — treatment requires simultaneous use of two reliable contraceptive methods, monthly pregnancy testing, and bosentan specifically requires non-hormonal methods since it reduces hormonal contraceptive plasma levels through CYP induction; combination with a PDE5 inhibitor is current guideline-recommended standard of care for pulmonary arterial hypertension.

Feature	Bosentan	Ambrisentan	Macitentan
Receptor target	Dual ETA + ETB	Selective ETA	Dual ETA + ETB
Hepatotoxicity	High (~10%) — monthly LFTs	Low	Low
CYP induction	Yes — many interactions	No	No
Key interaction	Cyclosporine contraindicated; reduces warfarin, hormonal contraceptives	Minimal	Minimal
Edema risk	Moderate	Higher	Moderate
Anemia risk	Low	Low	Yes — monitor hemoglobin
Key trial	BREATHE-1	ARIES-1, ARIES-2	SERAPHIN (45% reduction morbidity/mortality)

Rule	Detail
Contraindicated in pregnancy	Teratogenic in animals at sub-therapeutic doses — fetal cardiovascular and craniofacial malformations
Mandatory contraception	Two reliable methods simultaneously; bosentan requires non-hormonal methods (reduces hormonal contraceptive levels)
Monthly pregnancy test	Required for all women of childbearing potential throughout treatment
Bosentan: monthly LFTs	Stop or reduce dose if transaminases exceed 3× upper limit of normal — reversible on discontinuation
Combine with PDE5 inhibitor	Sildenafil or tadalafil added to endothelin receptor antagonist is current guideline-recommended combination for pulmonary arterial hypertension

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
Yanagisawa M, Kurihara H, Kimura S, et al.	A novel potent vasoconstrictor peptide produced by vascular endothelial cells.	Nature. 1988;332(6163):411–415
Davenport AP, Hyndman KA, Dhaun N, et al.	Endothelin.	Pharmacol Rev. 2016;68(2):357–418
Channick RN, Simonneau G, Sitbon O, et al.	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.	Lancet. 2001;358(9288):1119–1123
Rubin LJ, Badesch DB, Barst RJ, et al.	Bosentan therapy for pulmonary arterial hypertension.	N Engl J Med. 2002;346(12):896–903
Galiè N, Olschewski H, Oudiz RJ, et al.	Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ARIES study 1 and 2.	Circulation. 2008;117(23):3010–3019
Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators.	Macitentan and morbidity and mortality in pulmonary arterial hypertension.	N Engl J Med. 2013;369(9):809–818
Galiè N, Humbert M, Vachiery JL, et al.	2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.	Eur Heart J. 2016;37(1):67–119
Humbert M, Kovacs G, Hoeper MM, et al.	2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.	Eur Heart J. 2022;43(38):3618–3731